BrainStorm to Present at SVB Leerink 10th Global Healthcare Conference

Rhea-AI Summary

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) announced participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021. Dr. Stacy Lindborg, EVP and head of Global Clinical Research, will present a corporate update at 8:40 AM Eastern Time. A live webcast of the presentation can be accessed via the provided link. The company focuses on developing adult stem cell therapies for neurodegenerative diseases. Caution is advised regarding forward-looking statements about clinical trials and financial requirements.

NEW YORK, Feb. 23, 2021 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today that members of the management team will participate in the 10^th Annual SVB Leerink Global Healthcare Conference.

Dr. Stacy Lindborg, the Company's EVP, head of Global Clinical Research will deliver a corporate update on February 26^th at 8.40 AM Eastern Time. The live webcast of Dr. Lindborg's presentation can be accessed at: https://bit.ly/3qMP3mJ

Safe-Harbor Statement 

Statements in this announcement other than historical data and information, including statements regarding future clinical trial enrollment and data, constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, BrainStorm's need to raise additional capital, BrainStorm's ability to continue as a going concern, regulatory approval of BrainStorm's NurOwn® treatment candidate, the success of BrainStorm's product development programs and research, regulatory and personnel issues, development of a global market for our services, the ability to secure and maintain research institutions to conduct our clinical trials, the ability to generate significant revenue, the ability of BrainStorm's NurOwn® treatment candidate to achieve broad acceptance as a treatment option for ALS or other neurodegenerative diseases, BrainStorm's ability to manufacture and commercialize the NurOwn® treatment candidate, obtaining patents that provide meaningful protection, competition and market developments, BrainStorm's ability to protect our intellectual property from infringement by third parties, heath reform legislation, demand for our services, currency exchange rates and product liability claims and litigation,; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at http://www.sec.gov. These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

CONTACTS 
Investor Relations:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Phone: +1 646-465-1138
cdavis@lifesciadvisors.com

Media:
Paul Tyahla
SmithSolve
Phone: + 1-973-713-3768
Paul.tyahla@smithsolve.com 

View original content to download multimedia:http://www.prnewswire.com/news-releases/brainstorm-to-present-at-svb-leerink-10th-global-healthcare-conference-301233461.html

SOURCE BrainStorm Cell Therapeutics Inc.

FAQ

What is the date and time of BrainStorm's presentation at the SVB Leerink Conference?

BrainStorm's presentation is scheduled for February 26, 2021, at 8:40 AM Eastern Time.

Who will present on behalf of BrainStorm at the conference?

Dr. Stacy Lindborg, EVP and head of Global Clinical Research, will deliver the presentation.

How can I access the live webcast of BrainStorm's presentation?

The live webcast can be accessed at this link: https://bit.ly/3qMP3mJ.

What is the focus of BrainStorm Cell Therapeutics?

BrainStorm focuses on developing adult stem cell therapies for neurodegenerative diseases.

What risks are associated with BrainStorm's forward-looking statements?

Risks include the need for additional capital, regulatory approvals, and the potential for market acceptance of their NurOwn® treatment.